Results 61 to 70 of about 4,251 (181)

Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real‐World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T‐Cell Era

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Allogeneic hematopoietic cell transplantation (alloHCT) remains a curative option for relapsed or refractory (r/r) mantle cell lymphoma (MCL), although its role has shifted in the era of Bruton tyrosine kinase inhibition (BTKi) and chimeric antigen receptor T‐cell (CAR‐T) therapy.
Enver Aydilek, Paolo Mazzeo, Justin Hasenkamp, Markus Maulhardt, Tobias Tix, Evgenii Shumilov, Gerald Wulf   +6 more
wiley   +1 more source

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

, 2023
ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia.
Woyach J. A., Ghia P., Seymour J. F., Kater A. P., Mato A., O'Brien S., Jurczak W., de Borja M., Bajwa N., Munir T., Byrd J. C., Furman R. R., Miranda P., Chanan-Khan A., Stilgenbauer S., Higgins K., Brown J. R., John E.   +17 more
core   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 845-849, June 2026.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma [PDF]

Zanubrutinib and acalabrutinib have demonstrated efficacy in separate single-arm clinical trials in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Shah, B., Ren, S., Srivastava, T., Yang, K., Xu, S., Saba, N.S., Gautam, R., Williams, R., Challagulla, S., Tam, C.S.   +9 more
core   +1 more source

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases

Journal of Comparative Effectiveness Research
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL ...
Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun, Zhijie Ding, Marie-Helene Lafeuille, Priyanka Gogna, Bruno Emond, Michael Fradley   +9 more
doaj   +1 more source

In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia

Scientific Reports
Ibrutinib and acalabrutinib are first- and next-generation Bruton Tyrosine Kinase inhibitors (BTKi), respectively, approved for chronic lymphocytic leukemia (CLL).
Raúl Córdoba, Antoni Bayés-Genís, Ana Muntañola, Dolors Colomer, Jorge Castro, Carolina Leiva, Esther Álvarez, Eduardo Zatarain-Nicolas   +7 more
doaj   +1 more source

Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy

Фармакоэкономика
Objective: to conduct a clinical and economic study of acalabrutinib for the treatment of adult patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy in the Russian Federation.Material and ...
S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

American Journal of Hematology, Volume 101, Issue 7, Page 1516-1521, July 2026.
Jennifer A. Woyach, Relja Popovic, Emily L. Rossi, Sanjana Singh, Toshihiko Oki, Tanya S. Rosenberg, Chen Qian, Michael Moran, Zihuan Liu, Michelle Boyer, Jeffrey Jones, Richard R. Furman, William Wierda, Jason Gotlib, Stephen J. Schuster, Brenda Chyla, Matthew S. Davids   +16 more
wiley   +1 more source

Successful Treatment of Evans Syndrome Onset With Zanubrutinib in Combination With Romiplostim During Venetoclax Treatment in a Patient With Chronic Lymphocytic Leukemia: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) can be complicated by autoimmune cytopenias, including autoimmune hemolytic anemia and immune thrombocytopenia (ITP), as observed in Evans syndrome. We report the case of a 75‐year‐old man with CLL who developed steroid‐ and rituximab‐refractory Evans syndrome during the ramp‐up phase of venetoclax treatment.
Vanessa Innao, Alessia Paola Maria Barbagallo, Oriana Bianco, Valerio Leotta, Ugo Consoli   +4 more
wiley   +1 more source

Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

, 2021
Calquence® (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated ...
Molly S. Adam, Aaron M. Stewart, Jesus A. Rosales, David T. Vodak, Adam Smith, Michael M. Morgen, Deanna M. Mudie, Nishant Biswas, Christopher D. Craig   +8 more
core   +1 more source